320-x-100_uti_gold.jpg" alt="Advertisement">
Orchid Pharma gains on partnering with Cipla to launch antibiotic Cefepime-Enmetazobactam in India
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Orchid Pharma is currently trading at Rs. 1150.35, up by 10.50 points or 0.92% from its previous closing of Rs. 1139.85 on the BSE.
The scrip opened at Rs. 1161.75 and has touched a high and low of Rs. 1188.10 and Rs. 1140.40 respectively. So far 9237 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1358.80 on 26-Feb-2024 and a 52 week low of Rs. 432.35 on 26-Oct-2023.
Last one week high and low of the scrip stood at Rs. 1255.05 and Rs. 1136.00 respectively. The current market cap of the company is Rs. 5852.98 crore.
The promoters holding in the company stood at 69.84%, while Institutions and Non-Institutions held 19.69% and 10.47% respectively.
Orchid Pharma has launched its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications. In a landmark collaboration,
Orchid Pharma has partnered with Cipla to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India. The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in the fight against AMR, a growing global health issue, reinforcing India’s leadership in medical innovation. This collaboration will set a new benchmark for addressing critical healthcare challenges through strategic partnerships and advanced research.
The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence. This collaboration aims to ensure that this life-saving medication reaches healthcare providers across India as quickly and efficiently as possible.
Orchid Pharma, established as an export-oriented unit (EOU), is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.
